Hevascol

Hevascol is a radiographic contrast agent whose active ingredient is ethiodized oil. It is supplied as a sterile injectable preparation, though specific strength and dosage form details are not publicly disclosed. Marketed in the European Union and available by prescription only, Hevascol is used in imaging procedures that require high‑density iodine to enhance visualization of vascular and lymphatic structures for diagnostic and interventional purposes in clinical practice.

Hevascol is indicated for several specialized imaging and therapeutic procedures that require iodine‑based contrast.

- Lymphangiography to delineate lymphatic vessels and nodes. - Embolization procedures where a radiopaque medium assists in occluding abnormal vessels. - Imaging of tumor vascularization to assess blood supply to neoplastic lesions. - Intra‑arterial angiography for detailed visualization of arterial anatomy. - Evaluation of vascular malformations such as arteriovenous fistulas. - Assessment of lymphatic drainage disorders in postoperative or congenital settings.

Adverse reactions to Hevascol are generally related to its iodine content and the oil base, and they can range from mild to severe.

Common: - Mild pain or burning sensation at the injection site lasting a few minutes. - Transient flushing or warmth sensation throughout the body shortly after administration. - Nausea or mild gastrointestinal discomfort that resolves without treatment. - Headache or dizziness occurring within the first hour post‑injection.

Serious: - Acute allergic reactions including urticaria, bronchospasm, or anaphylaxis requiring emergency care. - Embolic complications such as vessel occlusion leading to tissue ischemia. - Pulmonary oil embolism presenting with respiratory distress or hypoxia. - Significant renal function decline or contrast‑induced nephropathy in susceptible patients.

When using Hevascol, clinicians should observe several precautionary measures to minimize risks and ensure appropriate patient selection.

- Verify the patient has no known allergy to iodine‑containing contrast agents. - Assess thyroid function, especially in patients with hyperthyroidism or thyroid disorders. - Evaluate renal function prior to administration, as impaired kidneys may affect iodine clearance. - Avoid use in pregnant or breastfeeding women unless the diagnostic benefit outweighs potential risk. - Monitor for signs of embolic events in patients with pre‑existing vascular abnormalities. - Ensure proper injection technique to prevent extravasation or inadvertent intra‑arterial delivery. - Inform patients about possible transient sensations such as warmth or flushing.

Hevascol may interact with other agents that affect iodine handling, renal function, or coagulation.

Avoid: - Concurrent use of other iodinated contrast media within 24 hours. - High‑dose thyroid hormone preparations that could exacerbate iodine load.

Use with caution: - Nephrotoxic drugs such as aminoglycosides or NSAIDs. - Anticoagulants or antiplatelet agents that increase bleeding risk at injection sites. - Diuretics that may alter renal clearance of iodine. - Beta‑blockers that can mask early signs of anaphylaxis.